Biocon Limited has informed the Exchange that Record date for the purpose of Dividend is 03-Jul-2026.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon Limited's Board meeting on May 7, 2026 approved multiple items: (1) Audited financial results for Q4 and FY ended March 2026, (2) Recommended final dividend of Rs. 0.50 per equity share (10% on face value Rs. 5) for FY2026, with record date July 3, 2026 and payment by August 31, 2026, (3) Appointed S.R. Batliboi & Associates LLP as new statutory auditors replacing B S R & Co. LLP for 5 years, (4) Designated Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer as Senior Management Personnel, (5) Approved appointment of 6 new Independent Directors including Rajiv Malik, Daniel Bradbury, Peter Piot, Arun Chandavarkar, Nivruti Rai and Thomas Jason Roberts, (6) Approved acquisition of remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) through share swap of up to 87.92 lakh Biocon shares at Rs. 376.16 per share worth Rs. 330.73 crore, taking BBL ownership to ~99.99%, and (7) Approved Biocon Unity Long-Term Incentive Plan 2026.
The dividend recommendation provides income to shareholders though the amount is modest. The BBL acquisition consolidating ownership to ~99.99% simplifies corporate structure and could unlock value. New director appointments bring pharma industry expertise. Share issuance for BBL acquisition will dilute existing shareholders by ~87.92 lakh shares.